Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Julphar
Chinese Patent Office
Johnson and Johnson
Argus Health
Teva
Express Scripts
Farmers Insurance

Generated: April 20, 2018

DrugPatentWatch Database Preview

STATOBEX-G Drug Profile

« Back to Dashboard

Which patents cover Statobex-g, and what generic alternatives are available?

Statobex-g is a drug marketed by Teva and is included in one NDA.

The generic ingredient in STATOBEX-G is phendimetrazine tartrate. There are five drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.
Drug patent expirations by year for STATOBEX-G
Synonyms for STATOBEX-G
(2R,3R)-2,3-bis(oxidanyl)butanedioic acid; (2S,3S)-3,4-dimethyl-2-phenyl-morpholine
(2R,3R)-2,3-dihydroxybutanedioic acid; (2S,3S)-3,4-dimethyl-2-phenylmorpholine
(2S,3S)-3,4-Dimethyl-2-phenylmorpholine L-(+)-tartrate (1:1)
21102-82-9
2233-26-3
238P764
50-58-8
6985IP0T80
A828189
AC1L3R57
AC1Q5R36
Adipost
ALPHAZINE
Bontril (TN)
BONTRIL PDM
CAM-METRAZINE
D-3,4-Dimethyl-2-phenyl-morpholine tartrate
D02080
DI-METREX
DTXSID70198165
EINECS 200-051-0
HE004837
K631
L(+)-TARTARIC ACID; PHENDIMETRAZINE
LS-92795
MELFIAT-105
Metra
Morpholine, 3,4-dimethyl-2-phenyl-, (+)-, tartrate (1:1)
Morpholine, 3,4-dimethyl-2-phenyl-, (+)-, tartrate (1:1) (8CI)
Morpholine, 3,4-dimethyl-2-phenyl-, (2S-trans)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)
Morpholine, 3,4-dimethyl-2-phenyl-, (2S,3S)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
Morpholine, 3,4-dimethyl-2-phenyl-, tartrate, D-
PHENAZINE-35
Phendimetrazine hydrogen tartrate
Phendimetrazine tartrate (USP)
Phendimetrazine tartrate [USAN]
Phendimetrazine tartrate [USP]
phendimetrazine tartrate, (2S-trans(R-(R*,R*)))-isomer
Prelu 2
Prelu-2
SCHEMBL160375
Sodium alginate, viscosity ~100mp.s
SPRX
SPRX-105
SPRX-3
Statobex
UNII-6985IP0T80
X-TROZINE L.A
X-trozine L.A.

US Patents and Regulatory Information for STATOBEX-G

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva STATOBEX-G phendimetrazine tartrate TABLET;ORAL 085095-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Colorcon
Cerilliant
Boehringer Ingelheim
Queensland Health
Cantor Fitzgerald
Johnson and Johnson
Accenture
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.